NASDAQ:LEXX Lexaria Bioscience (LEXX) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free LEXX Stock Alerts $2.21 -0.06 (-2.64%) (As of 09:43 AM ET) Add Compare Share Share Today's Range$2.20▼$2.2450-Day Range$1.99▼$6.2552-Week Range$0.65▼$6.85Volume5,182 shsAverage Volume420,835 shsMarket Capitalization$28.49 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Lexaria Bioscience alerts: Email Address Lexaria Bioscience MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside429.8% Upside$12.00 Price TargetShort InterestHealthy4.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.32Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.60) to ($0.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.24 out of 5 starsMedical Sector514th out of 910 stocksPharmaceutical Preparations Industry237th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingLexaria Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLexaria Bioscience has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.25% of the float of Lexaria Bioscience has been sold short.Short Interest Ratio / Days to CoverLexaria Bioscience has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lexaria Bioscience has recently decreased by 35.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLexaria Bioscience does not currently pay a dividend.Dividend GrowthLexaria Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LEXX. Previous Next 1.8 News and Social Media Coverage News SentimentLexaria Bioscience has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lexaria Bioscience this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for LEXX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Lexaria Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lexaria Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.61% of the stock of Lexaria Bioscience is held by insiders.Percentage Held by InstitutionsOnly 13.06% of the stock of Lexaria Bioscience is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lexaria Bioscience are expected to grow in the coming year, from ($0.60) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexaria Bioscience is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexaria Bioscience is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexaria Bioscience has a P/B Ratio of 6.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About Lexaria Bioscience Stock (NASDAQ:LEXX)Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Read More LEXX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LEXX Stock News HeadlinesApril 17, 2024 | msn.comLexaria Bioscience, BioSig Technologies, BIMI Holdings among healthcare moversApril 16, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 StudyApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 5, 2024 | morningstar.comLexaria Bioscience Corp LEXXMarch 19, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Marks 2024 Milestone with FDA Clearance for Planned U.S. Phase 1b Hypertension TrialMarch 18, 2024 | proactiveinvestors.comLexaria Bioscience Revolutionizes Drug Delivery with DehydraTECH for GLP-1 drugMarch 15, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFOMarch 14, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Appoints Nelson Cabatuan as Chief Financial OfficerApril 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… March 7, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Awards Contract For Next GLP-1 Human Pilot StudyMarch 5, 2024 | msn.comLexaria to test DehydraTECH GLP-1 product for weight loss, diabetesMarch 4, 2024 | finanznachrichten.deLexaria Bioscience Corp.: 7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal StudyMarch 4, 2024 | finance.yahoo.com7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal StudyMarch 1, 2024 | msn.comLexaria slips despite FDA nod to test blood pressure drugFebruary 18, 2024 | finance.yahoo.comThis Lexaria Bioscience Insider Increased Their Holding By 23% Last YearFebruary 16, 2024 | finance.yahoo.comLexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 15, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 15, 2024 | finance.yahoo.comLexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 13, 2024 | theglobeandmail.comLexaria Bioscience’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Improves Delivery of GLP-1 DrugJanuary 30, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) To Hit High Ground in Q2/Q3 2024 with Animal, Human GLP-1 StudiesJanuary 30, 2024 | finance.yahoo.comLexaria's Submits Investigational New Drug ApplicationJanuary 22, 2024 | finance.yahoo.comLEXX’ Sweet Opportunity in GLP-1sJanuary 22, 2024 | investorplace.comLEXX Stock Earnings: Lexaria Bioscience Reported Results for Q1 2024January 16, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Unveils Extensive Planned 2024 GLP-1 Study ProgramJanuary 16, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Looking to Grow Revenue, Commercial Opportunities Through LicensingJanuary 10, 2024 | finanznachrichten.deNetworkNewsWire: GLP-1: Beyond Diabetes, a Blockbuster Horizon BeckonsJanuary 9, 2024 | finance.yahoo.comLexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery PlatformSee More Headlines Receive LEXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Next Earnings (Estimated)7/12/2024Fiscal Year End8/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LEXX CUSIPN/A CIK1348362 Webwww.lexariabioscience.com Phone(250) 765-6424FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+429.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,660,000.00 Net MarginsN/A Pretax Margin-1,417.36% Return on Equity-133.97% Return on Assets-118.89% Debt Debt-to-Equity RatioN/A Current Ratio66.29 Quick Ratio66.29 Sales & Book Value Annual Sales$404,726.00 Price / Sales72.11 Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book6.86Miscellaneous Outstanding Shares12,886,000Free Float11,905,000Market Cap$29.19 million OptionableNot Optionable Beta0.94 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Christopher A. Bunka (Age 62)Chairman & CEO Comp: $291.19kMr. John M. Docherty M.Sc. (Age 55)President & Director Comp: $290.46kMr. Nelson D. Cabatuan CPA (Age 45)Chief Financial Officer Kristin HamiltonDirector of OperationsVanessa CarleHead of LegalDr. Philip N. Ainslie Ph.D.Advisor & ConsultantMore ExecutivesKey CompetitorsCASI PharmaceuticalsNASDAQ:CASISpruce BiosciencesNASDAQ:SPRBAprea TherapeuticsNASDAQ:APRETheratechnologiesNASDAQ:THTXViracta TherapeuticsNASDAQ:VIRXView All CompetitorsInstitutional OwnershipWelch Group LLCBought 24,000 shares on 4/9/2024Ownership: 0.194%Invenomic Capital Management LPSold 32,351 shares on 2/14/2024Ownership: 7.011%Cowen AND Company LLCBought 256,327 shares on 2/8/2024Ownership: 2.455%View All Institutional Transactions LEXX Stock Analysis - Frequently Asked Questions Should I buy or sell Lexaria Bioscience stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lexaria Bioscience in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LEXX shares. View LEXX analyst ratings or view top-rated stocks. What is Lexaria Bioscience's stock price target for 2024? 1 analysts have issued 12-month target prices for Lexaria Bioscience's shares. Their LEXX share price targets range from $12.00 to $12.00. On average, they predict the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 429.8% from the stock's current price. View analysts price targets for LEXX or view top-rated stocks among Wall Street analysts. How have LEXX shares performed in 2024? Lexaria Bioscience's stock was trading at $1.25 at the start of the year. Since then, LEXX shares have increased by 81.2% and is now trading at $2.2650. View the best growth stocks for 2024 here. Are investors shorting Lexaria Bioscience? Lexaria Bioscience saw a decline in short interest in March. As of March 31st, there was short interest totaling 490,400 shares, a decline of 35.0% from the March 15th total of 754,500 shares. Based on an average daily trading volume, of 465,300 shares, the days-to-cover ratio is presently 1.1 days. Approximately 4.3% of the shares of the stock are sold short. View Lexaria Bioscience's Short Interest. When is Lexaria Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, July 12th 2024. View our LEXX earnings forecast. Who are Lexaria Bioscience's major shareholders? Lexaria Bioscience's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Welch Group LLC (0.19%). View institutional ownership trends. How do I buy shares of Lexaria Bioscience? Shares of LEXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LEXX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
